Stabl, developed by our founding team, is the foundation of our biomarker discovery platform — the result of over 10 years of interdisciplinary research in multiomics, systems biology, and machine learning. Designed to extract robust and interpretable biological fingerprints from complex datasets, Stabl enables a new generation of clinically actionable biomarkers. Its unique ability to extract only the most relevant biomarkers from a sea of multiomic data unlocks broad applications across diagnostics, precision prevention, and therapeutic development — transforming how we understand, detect, and treat disease.